ArriVent BioPharma (NASDAQ:AVBP) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of ArriVent BioPharma (NASDAQ:AVBP – Free Report) from a sell rating to a hold rating in a report issued on Saturday morning,Wall Street Zen reports.

Other equities analysts also recently issued research reports about the stock. Truist Financial lifted their price objective on shares of ArriVent BioPharma from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Thursday, October 15th. Oppenheimer restated an “outperform” rating and issued a $25.00 price target on shares of ArriVent BioPharma in a research report on Monday, October 26th. Cantor Fitzgerald restated an “overweight” rating on shares of ArriVent BioPharma in a research report on Thursday. Finally, BTIG Research reaffirmed a “buy” rating and issued a $29.00 price target on shares of ArriVent BioPharma in a report on Friday, October 16th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, ArriVent BioPharma currently has an average rating of “Moderate Buy” and a consensus price target of $24.89.

Read Our Latest Stock Analysis on AVBP

ArriVent BioPharma Trading Down 0.5%

NASDAQ AVBP traded down $0.06 on Friday, hitting $13.01. 616,141 shares of the stock traded hands, compared to its average volume of 1,468,157. The stock has a 50-day moving average of $21.36 and a 200 day moving average of $26.40. ArriVent BioPharma has a twelve month low of $11.36 and a twelve month high of $35.83. The company has a market capitalization of $672.88 million, a P/E ratio of -3.61 and a beta of 1.66.

ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. The firm had revenue of $5.00 million during the quarter, compared to the consensus estimate of $0.80 million. As a group, equities research analysts expect that ArriVent BioPharma will post -3.81 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Montanova Capital LLC increased its position in ArriVent BioPharma by 2.6% in the second quarter. Montanova Capital LLC now owns 4,515,531 shares of the company’s stock worth $156,870,000 after buying an additional 114,448 shares during the period. Hhlr Advisors LTD. acquired a new position in shares of ArriVent BioPharma during the second quarter valued at $136,498,000. BlackRock Inc. acquired a new position in shares of ArriVent BioPharma during the second quarter valued at $112,919,000. General Catalyst Group Management LLC acquired a new position in shares of ArriVent BioPharma during the second quarter valued at $51,929,000. Finally, Vivo Capital LLC bought a new position in shares of ArriVent BioPharma during the first quarter worth about $20,438,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

(Get Free Report)

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.

Further Reading

Analyst Recommendations for ArriVent BioPharma (NASDAQ:AVBP)

Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.